Cagrilintide

Cagrilintide | Peptide Complex

Metabolic

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, currently being investigated in clinical trials as a monotherapy and in combination with semaglutide (as "CagriSema") for obesity and type 2 diabetes management. Amylin is a pancreatic peptide co-secreted with insulin that regulates appetite, gastric emptying, and glucagon secretion. Cagrilintide has been engineered for extended half-life and receptor potency, producing sustained amylinergic signaling that complements GLP-1 class compounds through distinct and additive mechanisms.

• Amylin Receptor Agonism — Cagrilintide activates amylin receptors (AMY1-3) in the area postrema and hypothalamus, reducing food intake and promoting satiety through pathways entirely independent of GLP-1 receptor signaling.

• Complementary Weight Reduction — When combined with GLP-1 agonists in research, cagrilintide demonstrates additive to synergistic weight loss effects, with CagriSema trials showing weight reductions exceeding those of semaglutide alone.

• Glucagon Suppression — Amylinergic signaling suppresses postprandial glucagon release from pancreatic alpha cells, contributing to improved glycemic control in research models of type 2 diabetes.

• Gastric Emptying Regulation — Cagrilintide slows gastric emptying through amylin receptor pathways, reducing postprandial glucose spikes and prolonging satiety signals after meals in metabolic research models.

• Central Appetite Regulation — Research indicates cagrilintide modulates hypothalamic and brainstem circuits governing energy homeostasis through amylin-specific pathways, representing a distinct neurological target from GLP-1 class appetite modulation.